Anja Engelke

3.0k total citations
15 papers, 264 citations indexed

About

Anja Engelke is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Anja Engelke has authored 15 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 10 papers in Immunology. Recurrent topics in Anja Engelke's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Anja Engelke is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Anja Engelke collaborates with scholars based in Germany, Switzerland and United Kingdom. Anja Engelke's co-authors include Michael Hallek, Kirsten Fischer, Stephan Stilgenbauer, Jasmin Bahlo, Barbara Eichhorst, Clemens‐Martin Wendtner, Valentin Goede, Petra Langerbeins, Hartmut Döhner and Paula Cramer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Anja Engelke

12 papers receiving 259 citations

Peers

Countries citing papers authored by Anja Engelke

Since Specialization

Citations

This map shows the geographic impact of Anja Engelke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja Engelke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja Engelke more than expected).

Fields of papers citing papers by Anja Engelke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja Engelke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja Engelke. The network helps show where Anja Engelke may publish in the future.

Co-authorship network of co-authors of Anja Engelke

This figure shows the co-authorship network connecting the top 25 collaborators of Anja Engelke. A scholar is included among the top collaborators of Anja Engelke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja Engelke. Anja Engelke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	CLL2-BXX Phase II Trials: Sequential, Targeted Treatment for Eradication of Minimal Residual Disease in Chronic Lymphocytic Leukemia 2018 ·Future Oncology ·Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna‐Maria Fink, Kirsten Fischer, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek	21
2	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy 2017 ·Drug Design Development and Therapy ·Othman Al‐Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek, Valentin Goede	12
3	BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG) 2017 ·Hematological Oncology ·Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, Othman Al‐Sawaf, Petra Langerbeins, Anja Engelke, Anna Maria Fink, Kirsten Fischer, (unknown), Ludwig Fischer von Weikersthal, Holger Hebart, Karl‐Anton Kreuzer, Matthias Ritgen, Michael Kneba, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek	6
4	BENDAMUSTINE (B), followed by OBINUTUZUMAB (G, GA101) and VENETOCLAX (A, ABT-199) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG PHASE-II-TRIAL of the German CLL Study Group (GCLLSG) 2017 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, (unknown), Petra Langerbeins, Anja Engelke, Anna Maria Fink, Kirsten Fischer, (unknown), Ludwig Fischer von Weikersthal, Holger Hebart, K.-A. Kreuzer, Matthias Ritgen, Michael Kneba, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek	0
5	Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL 2016 ·Leukemia ·Christian Maurer, Petra Langerbeins, Jasmin Bahlo, Paula Cramer, Anna‐Maria Fink, Natali Pflug, Anja Engelke, Julia von Tresckow, Gábor Kovács, Stephan Stilgenbauer, C-M Wendtner, Lothar Müller, Matthias Ritgen, (unknown), Kirsten Fischer, Michael Hallek, Barbara Eichhorst, (unknown)	35
6	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial 2016 ·Blood ·Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, Petra Langerbeins, Anna‐Maria Fink, Thomas Illmer, (unknown), (unknown), Matthias Ritgen, Kirsten Fischer, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek	9
7	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG) 2016 ·Blood ·Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, Petra Langerbeins, Anna‐Maria Fink, Hyatt Balke‐Want, Othman Al‐Sawaf, Till Seiler, Ludwig Fischer von Weikersthal, Holger Hebart, Kirsten Fischer, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek	6
8	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy 2016 ·Blood ·Carmen Herling, (unknown), (unknown), Janine Altmüller, Hölger Thiele, Jasmin Bahlo, Sandra Kluth, Giuliano Crispatzu, Marco Herling, Joanna Schiller, Anja Engelke, Eugen Tausch, Hartmut Döhner, Kirsten Fischer, Valentin Goede, Peter Nürnberg, Hans Christian Reinhardt, Stephan Stilgenbauer, Michael Hallek, Karl-Anton Kreuzer	71
9	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial 2015 ·Blood ·Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna‐Maria Fink, (unknown), Eugen Tausch, Kirsten Fischer, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böettcher, Barbara Eichhorst, Michael Hallek	14
10	Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset 2014 ·Blood ·(unknown), Mark Dixon, Richard Houghton, Kathryn Humphrey, Günter Fingerle‐Rowson, Karl‐Anton Kreuzer, Anja Engelke, Michael Hallek, Valentin Goede	6
11	Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study 2014 ·Blood ·Valentin Goede, Anja Engelke, Kirsten Fischer, Javier López Jiménez, (unknown), Martin J.S. Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W. Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Günter Fingerle‐Rowson, Michael Hallek	12
12	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. 2013 ·Journal of Clinical Oncology ·Valentin Goede, Kirsten Fischer, Kathryn Humphrey, Elina Asikanius, Raymonde Busch, Anja Engelke, Clemens‐Martin Wendtner, Olga Samoylova, Tatiana Chagorova, Marie‐Sarah Dilhuydy, (unknown), Thomas Illmer, Stephen Opat, Carolyn Owen, Karl Anton Kreuzer, Anton W. Langerak, Matthias Ritgen, Stephan Stilgenbauer, Michael Wenger, Michael Hallek	29
13	Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen 2012 ·Blood ·Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Raymonde Busch, Sebastian Böttcher, Jiřı́ Mayer, Peter Dreger, Christian Maurer, Anja Engelke, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Michael Hallek	43
14	Chronische lymphatische Leukämie 2012 ·Der Onkologe ·Anja Engelke, Claude P. Muller, Michael Hallek	0
15	The influence of platelet homogenates on thrombopoiesis in rabbits 1980 ·Thrombosis Research ·(unknown), Anne-Marie Mingers, Anja Engelke	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact